The national government took a new step in its economic deregulation agenda. After announcing the gradual end of the Tierra del Fuego regime through the reduction of tariffs for the importation of cell phones, it now focuses on the veterinary vaccine market, dominated for decades by a single local supplier.
Through Resolution 333/2025 published by Senasa, a new scheme for the importation of veterinary products registered abroad is enabled. Among the key points, the acceptance of international certifications stands out, the elimination of local technical requirements considered restrictive, and a new period of up to 90 business days to authorize products, replacing the lengthy processes that could take up to two years.
Blow to Biogénesis Bagó's monopoly
The regulatory change directly affects the foot-and-mouth disease vaccine business, which is mandatory throughout the country and was supplied by Biogénesis Bagó, the only laboratory authorized until now. The new regulatory framework incorporates recommendations from the National Commission for the Defense of Competition (CNDC), which identified artificial barriers that limited the entry of competitors.

One of the most controversial obstacles was the requirement for a test called Foot-and-Mouth Generalization Protection (PGP), eliminated in the new regulation for being obsolete and costly. It was also recognized as an obstacle the systematic refusal of Senasa to accept vaccines approved in countries with effective health programs, such as Paraguay or Uruguay.
Sturzenegger: "A closed market artificially raised prices"
The Minister of Deregulation, Federico Sturzenegger, spoke about it through social media. He explained that while in Argentina a single vaccine was sold at 1.20 dollars per dose, in Paraguay the price was 0.35 dollars and in Uruguay 0.72 dollars. He also denounced that the same laboratory supplying the Argentine market sells cheaper in other countries.
During a radio interview, he assured that this change "reduces costs for the livestock chain by approximately 100 million dollars annually." According to him, the requirement that the vaccine contains four strains—two of which no longer circulate—functioned as a technical barrier designed to exclude other laboratories.









